SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: Charles Tutt who wrote (637)10/18/1999 5:25:00 PM
From: PDL  Read Replies (2) | Respond to of 1298
 
With CEGE's cash and ownership interest in Abgenix valued at about $5.50/share, GENZ is acquiring CEGE's patent portfolio, people and operations for $4.50/share. I won't pretend to know how to properly value these but, on the surface and IMHO, GENZ is getting a bargain.



To: Charles Tutt who wrote (637)10/18/1999 10:39:00 PM
From: Orwell  Read Replies (1) | Respond to of 1298
 
GENZ is buying CEGE now BECAUSE it is a good deal. If they wait too much longer, CEGE's value will become more and more apparent, and they the price will increase. I was a former owner of GENZ, and looking to buy back at lower prices. I think today's downward action on GENZ due to takeover makes it a strong buy now.

O.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News